Silexion Therapeutics Corp
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| U.S. dollars in thousands | ||
| Assets | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $2,229 | $5,991 |
| Restricted cash | 29 | 27 |
| Prepaid expenses | 1,372 | 570 |
| Other current assets | 111 | 49 |
| TOTAL CURRENT ASSETS | 3,741 | 6,637 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | 62 | 57 |
| Long-term deposit and other non-current assets | 75 | 84 |
| Property and equipment, net | 20 | 25 |
| Operating lease right-of-use asset | 348 | 412 |
| TOTAL NON-CURRENT ASSETS | 505 | 578 |
| TOTAL ASSETS | $4,246 | $7,215 |
F - 3
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(except share data)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| U.S. dollars in thousands | ||
| Liabilities and shareholders’ equity | ||
| CURRENT LIABILITIES: | ||
| Trade payables | $1,180 | $787 |
| Current maturities of operating lease liability | 199 | 182 |
| Employee related obligations | 628 | 879 |
| Other account payable | 984 | 910 |
| Private warrants to purchase ordinary shares (including $* due to related party, as of June 30, 2026 and December 31, 2025) | * | * |
| Related Party Promissory Note | 985 | - |
| TOTAL CURRENT LIABILITIES | 3,976 | 2,758 |
| NON-CURRENT LIABILITIES: | ||
| Long-term operating lease liability | 226 | 286 |
| Related Party Promissory Note | - | 1,568 |
| TOTAL NON-CURRENT LIABILITIES | $226 | $1,854 |
| TOTAL LIABILITIES | $4,202 | $4,612 |
| SHAREHOLDERS' EQUITY: Ordinary shares ($0.135 par value per share, 5,900,000 and 900,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 1,179,844 and 312,665 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively) | 160 | 42 |
| Additional paid-in capital | 61,334 | 57,727 |
| Accumulated deficit | (61,450) | (55,166) |
| TOTAL SHAREHOLDERS' EQUITY | $44 | $2,603 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $4,246 | $7,215 |
All share amounts reflect a 1-for-10 reverse share split effected on May 28, 2026, as discussed in Note 1(d)
F - 4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.